Insmed Inc.
Insmed Announces Redemption of $225 Million Convertible Senior Notes
Summary
On June 27, 2024, Insmed Incorporated announced the redemption of all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes due 2025. The redemption will be effected on August 9, 2024, at a redemption price of 100% of the principal amount plus accrued and unpaid interest. Note holders may convert their notes into shares of common stock up until August 8, 2024.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement